Jennifer A. Woyach, MD, discusses background and updated findings from the phase 1/2 BRUIN study of pirtobrutinib for the treatment of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after prior treatment with a covalent Bruton tyrosine kinase inhibitor.
Jennifer A. Woyach, MD, hematologist-oncologist, professor, the Division of Hematology, the Ohio State University Comprehensive Cancer Center– James, discusses background and updated findings from the phase 1/2 BRUIN study (NCT03740529) of pirtobrutinib (Jaypirca) for the treatment of heavily pretreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after prior treatment with a covalent Bruton tyrosine kinase (BTK) inhibitor.
Findings presented at ASH 2023 showed that at a median follow-up of 27.5 months, patients with CLL who had previously been treated with a covalent BTK inhibitor had a median progression-free survival (PFS) of 19.4 months with pirtobrutinib (95% CI, 16.6-22.1). At a median follow-up of 27.6 months, the median PFS in the BCL-2 inhibitor–naive group with pirtobrutinib was 23.0 months (95% CI, 19.6-28.4), and at a median follow-up of 22.2 months, patients in the BCL-2 inhibitor–exposed group had a median PFS of 15.9 months (95% CI, 13.6-17.5).
Transcription:
0:09 | At ASH 2023, we discussed the long-term follow-up of pirtobrutinib in patients with relapsed/refractory CLL, which is a follow-up of the BRUIN phase 1/2 trial. And here we had about 30 months of follow-up on the study, and focused specifically on the group of patients who had received the prior covalent BTK inhibitor, so either ibrutinib, acalabrutinib [Calquence], or zanubrutinib [Brukinsa]. This cohort was about 280 patients. And then we broke that cohort down further into the patients who had previously been treated with the BCL2 inhibitor and the patients who were previously naive to a BCL2 inhibitor.
0:44 | Overall response rate has been reported before, it's over 80%, and it did not vary based upon whether patients had received a prior BCL2 inhibitor or not. We also see with long-term follow-up [that the] median progression-free survival is 19.4 months for that entire cohort. This actually did look a little bit different in the patients who had previously been treated with a BCL2 inhibitor and those that had not. Those patients who had received a prior BCL2 inhibitor had a median progression-free survival of about 16 months [and] those that had not had a median PFS of about 23 months. Importantly, the patients who had received a prior BCL2 inhibitor, as you would expect, were just a higher-risk group of patients in general, so they obviously had had more prior therapies. A number of them and either had [chimeric antigen receptor] T cells or even allogeneic stem cell transplants too, kind of showing us that the later in lines of therapy, as you would expect, the PFS is going to be shorter.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More